Table 3.
Spearman correlation analyses between PCSK9 and platelet activation makers according to diabetes status
| Whole cohort (n = 1027) | DM (n = 277) | Non-DM (n = 750) | ||||
|---|---|---|---|---|---|---|
| r | P | r | P | r | P | |
| sP-selectin | 0.158 | 0.015 | 0.181 | 0.001 | 0.141 | 0.065 |
| sCD40L | 0.176 | < 0.001 | 0.279 | < 0.001 | 0.086 | 0.001 |
| Without prior antiplatelet therapy (n = 897) | n = 225 | n = 672 | ||||
| sP-selectin | 0.133 | 0.012 | 0.216 | < 0.001 | 0.105 | 0.057 |
| sCD40L | 0.219 | < 0.001 | 0.317 | < 0.001 | 0.187 | < 0.001 |
PCSK9 proprotein convertase subtilisin/kexin type 9, DM diabetes mellitus, non-DM non-diabetes mellitus, sP-selectin soluble P-selectin, sCD40L soluble CD40 ligand